# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001493152-25-017923
**Filing Date:** 2025-10
**Character Count:** 9570
**Document Hash:** feb02c58b3f7a26889e2c334017b5c06
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017923.hdr.sgml**: 20251014

**ACCESSION NUMBER**: 0001493152-25-017923

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251014

**FILED AS OF DATE**: 20251014

**DATE AS OF CHANGE**: 20251014

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41677
- **FILM NUMBER:** 251389712

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October 2025

**Commission File Number: 001-41677**

**CytoMed Therapeutics Limited**

(Exact name of registrant as specified in its charter)

**1 Commonwealth Lane**

**#08-22**

**Singapore 149544**

**(Address of Principal Executive Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On October 14, 2025, CytoMed Therapeutics Limited (the "Company") issued a press release announcing it has submitted a cash bid of an undisclosed sum in relation to a potential acquisition of potentially synergistic assets of TC BioPharm Limited (" TCBL"), which entered administration on October 2, 2025.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

**Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated October 14, 2025, titled: "CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets"](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CytoMed Therapeutics Limited** | **CytoMed Therapeutics Limited** |
|  | By: | */s/ CHOO Chee Kong* |
|  | Name: | CHOO Chee Kong |
| Date: October 14, 2025 | Title: | Director and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

**CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets**

**Singapore, Singapore – (October 14, 2025) –** CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that it has submitted a cash bid for an undisclosed sum with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP who were appointed as joint administrators to TC BioPharm Limited ("TCBL") on October 2, 2025, in relation to a potential acquisition of potentially synergistic assets of TCBL (the "Proposed Acquisition").

TCBL and CytoMed are both clinical stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment. TCBL has completed Phase I clinical trial, while CytoMed is currently conducting its Phase I ANGELICA Trial in Singapore under an Investigational New Drug (IND) application, evaluating its proprietary chimeric antigen receptor (CAR) T cells for a broad range of liquid and solid cancers.

This Proposed Acquisition is intended to strengthen and deepen CytoMed's expertise and knowledge in using allogeneic cell therapies for cancer treatment, enabling the Company to accelerate its commercialization timeline and advance its mission to provide affordable therapeutic options for patients, especially for no-option patients with unmet needs from all over the world.

"Based on our data, we believe there is encouraging potential in using donor-derived gamma delta T cells for cancer treatment," said Mr. Peter Choo, Chairman of CytoMed. "Our collaborator, MD Anderson Cancer Center (MDACC), recently published a paper highlighting the promise of this approach, as referenced in our announcement dated [October 2, 2025](https://www.sec.gov/Archives/edgar/data/1873093/000149315225016599/form6-k.htm). We believe that this allogeneic therapy is also safe in high doses and is cost-effective to manufacture at scale."

Chairman Mr. Peter Choo added, "China reportedly took recent steps to boost cell therapies in its hospitals which augurs well for our developing China strategy. Presently, CytoMed's mission is to leverage Southeast Asia's low-cost infrastructure to make cell therapies accessible to more patients. By combining our technologies, CytoMed aims to develop affordable T effector cells to benefit more patients."

This Proposed Acquisition represents CytoMed's second acquisition within approximately one year. As previously announced on [October 3, 2024](https://www.sec.gov/Archives/edgar/data/1873093/000149315224039293/form6-k.htm), we completed the asset acquisition of a licensed cord blood bank in Malaysia, one of only three licensed cord blood banks there. That acquisition provides access to rare and precious cord blood as cost-free raw materials for our strategic expansion into a new class of cord blood-derived therapeutics for auto-immune diseases and cancers due to its naïve cord properties.

The Proposed Acquisition will be funded by internal resources. More information will be announced when available. Shareholders and investors are advised to exercise caution when dealing in the Company's securities until further announcements are made.

**About CytoMed Therapeutics Limited (CytoMed)**

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A\*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit <u>www.cytomed.sg</u> and follow us on Twitter ("X") <u>@CytomedSG</u>, on <u>LinkedIn</u>, and <u>Facebook</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

**Contact :**

**CytoMed Therapeutics Limited**

enquiry@cytomed.sg

Attention : Evelyn Tan, Chief Corporate Officer